Conclusion With the completion of several cardiovascular and kidney outcome trials involving an increasing number of therapeutic agents, tremendous progress has been made in the management of individuals with type 2 diabetes and CKD
Safety is ensured through comprehensive initial screening and ongoing monitoring
For the full side effect profile, see our GLP-1 side effects guide
Understanding your options and what to expect Delivery timing and how the process works General questions before you decide The Link Between GLP-1/GIP Treatments and Vitamin B12 The relationship between GLP-1/GIP medicines and vitamin B12 status is an emerging area of clinical interest, though there is no official direct pharmacological link established between these therapies and B12 deficiency
The 6-month and 12-month cohorts were treated independently, so that any given individual could be included in either cohort, or in both, provided they had data available at the relevant time points
This is the single most effective intervention to protect lean mass during weight loss